. 2024 Mar 14;12(4):e03836-23. doi: 10.1128/spectrum.03836-23

TABLE 1.

In vitro activity of cefiderocol, BLBLI combinations, and other relevant antibiotics against P. aeruginosa and Acinetobacter spp. isolates^a^,^b

	FDC		MEM		CZA		C-T		MVB		I-R		ATM-AVI		FEP-TAN		SUL-DUR		(CST)
Isolates (n)	MIC₉₀ (mg/L)	S (%)	MIC₉₀ (mg/L)	S/I (%)	MIC₉₀ (mg/L)	S (%)	MIC₉₀ (mg/L)	S (%)	MIC₉₀ (mg/L)	S/I (%)	MIC₉₀ (mg/L)	S (%)	MIC₉₀ (mg/L)	S/I (%)	MIC₉₀ (mg/L)	S/I (%)	MIC₉₀ (mg/L)	S (%)	MIC₉₀ (mg/L)	S (%)
P. aeruginosa (950)	1	98.9	16	85.4	8	90.1	8	89.1	16	87.2	4	83.3	32	86.2	8	91.4	N/A	N/A	(1)	(99.7)
Acinetobacter spp. (501)^c	2	92.4	>16	54.7	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	4	97.0	(0.5)	(98.4)

^{^a}

ATM-AVI, aztreonam-avibactam; BLBLI, β-lactam/β-lactamase inhibitor; CST, colistin; C-T, ceftolozane-tazobactam; CZA, ceftazidime-avibactam; ECOFF, epidemiological cut-off; EUCAST, European Committee on Antimicrobial Susceptibility Testing; FDA, Food and Drug Administration; FDC, cefiderocol; FEP-TAN, cefepime-taniborbactam; I, susceptible, increased exposure; I-R, imipenem-relebactam; MEM, meropenem; MVB, meropenem-vaborbactam; N/A, not applicable; PD, pharmacodynamic; PK, pharmacokinetic; S, susceptibility; SUL-DUR, sulbactam-durlobactam.

^{^b}

Antibiotics were tested against P. aeruginosa and/or Acinetobacter spp. based on expected use in a real-world setting. Susceptibility was assessed according to EUCAST breakpoints (including non-species-specific PK/PD breakpoints, high-dosage breakpoints, and breakpoints for the agent without inhibitor, where applicable), except for sulbactam-durlobactam and colistin where FDA breakpoints and ECOFF values were used, respectively. Data on susceptibility to colistin are shown in parentheses as colistin is not recommended for monotherapy and is not associated with a clinical monotherapy breakpoint (as per EUCAST v.14.0 guidance).

^{^c}

Includes 458 A. baumannii complex isolates.